Symbols / GLTO
GLTO Chart
About
Galecto, Inc., a clinical-stage biotechnology company, develops molecule therapeutics for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company develops GB3226, a preclinical small molecule dual inhibitor of ENL-YEATS and FLT3 and GB1211, an oral small molecule inhibitor of galectin-3 to treat multiple types of oncology and liver disease indications. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 1.91B |
| Enterprise Value | 35.95M | Income | -15.84M | Sales | — |
| Book/sh | 5.02 | Cash/sh | 5.73 | Dividend Yield | — |
| Payout | 0.00% | Employees | 5 | IPO | — |
| P/E | — | Forward P/E | -33.43 | PEG | — |
| P/S | — | P/B | 6.32 | P/C | — |
| EV/EBITDA | -3.03 | EV/Sales | — | Quick Ratio | 3.28 |
| Current Ratio | 3.73 | Debt/Eq | 0.90 | LT Debt/Eq | — |
| EPS (ttm) | -12.11 | EPS next Y | -0.95 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2025-08-11 16:00 | ROA | -43.54% |
| ROE | -109.49% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 60.24M |
| Shs Float | 1.05M | Short Float | 11.72% | Short Ratio | 4.21 |
| Short Interest | — | 52W High | 38.33 | 52W Low | 2.01 |
| Beta | 1.46 | Avg Volume | 157.98K | Volume | 846.60K |
| Target Price | $46.75 | Recom | Strong_buy | Prev Close | $29.78 |
| Price | $31.75 | Change | 6.62% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$46.75
Mean price target
2. Current target
$31.75
Latest analyst target
3. DCF / Fair value
$-2.11
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$31.75
Low
$40.00
High
$57.00
Mean
$46.75
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-02-17 | init | UBS | — → Buy | $45 |
| 2026-02-17 | main | Guggenheim | Buy → Buy | $40 |
| 2026-01-07 | init | Leerink Partners | — → Outperform | $46 |
| 2025-12-08 | main | Guggenheim | Buy → Buy | $36 |
| 2025-12-01 | init | Guggenheim | — → Buy | $32 |
| 2024-10-17 | main | Oppenheimer | Outperform → Outperform | $10 |
| 2024-06-10 | main | Oppenheimer | Outperform → Outperform | $9 |
| 2023-09-28 | down | HC Wainwright & Co. | Buy → Neutral | — |
| 2023-08-21 | main | HC Wainwright & Co. | Buy → Buy | $2 |
| 2023-08-15 | down | SVB Leerink | Outperform → Market Perform | $2 |
| 2023-08-01 | reit | Oppenheimer | Outperform → Outperform | $12 |
| 2023-08-01 | reit | HC Wainwright & Co. | Buy → Buy | $12 |
| 2023-06-20 | init | Oppenheimer | — → Outperform | $12 |
| 2023-05-24 | reit | HC Wainwright & Co. | Buy → Buy | $12 |
| 2023-05-15 | init | HC Wainwright & Co. | — → Buy | $12 |
| 2023-03-17 | init | Cantor Fitzgerald | — → Overweight | $16 |
| 2023-03-10 | reit | Credit Suisse | — → Outperform | $6 |
| 2022-08-03 | main | SVB Leerink | — → Outperform | $13 |
| 2021-08-06 | main | Credit Suisse | — → Outperform | $7 |
| 2021-03-16 | main | Credit Suisse | — → Outperform | $12 |
- Galecto raises $316.3M as it develops blood cancer therapies - Stock Titan hu, 12 Feb 2026 08
- Galecto (GLTO) Is Up 15.3% After $316 Million Equity Raise And New Shelf Registration - What's Changed - Yahoo Finance Sun, 15 Feb 2026 08
- GLTO, MOVE: two penny stocks quadrupled today – but should you buy? - TradingView Mon, 10 Nov 2025 08
- Analysts Offer Insights on Healthcare Companies: Establishment Labs Holdings (ESTA) and Galecto (GLTO) - The Globe and Mail Fri, 20 Feb 2026 08
- GLTO: Guggenheim Maintains Buy Rating and Raises Price Target to $40 | GLTO Stock News - GuruFocus ue, 17 Feb 2026 14
- Galecto, Inc. Announces Pricing of $275 Million Underwritten Public Offering of Common Stock - Quiver Quantitative Wed, 11 Feb 2026 03
- Galecto stock falls after announcing public offering of common stock - Investing.com ue, 10 Feb 2026 08
- GLTO Stock Rises A Whopping 632% Pre-Market, But Retail Investors Remain Cautious - Stocktwits ue, 07 Oct 2025 07
- Why Is Galecto Stock (GLTO) Up 285% Today? - TipRanks Mon, 10 Nov 2025 08
- Guggenheim Maintains Galecto (GLTO) Buy Recommendation - Nasdaq Mon, 08 Dec 2025 08
- Galecto (GLTO) Is Up 21.3% After $316 Million Equity Raise and New $150 Million Shelf Registration - Sahm Mon, 16 Feb 2026 08
- Cancer drug developer Galecto plans stock sale to fund antibody trials - Stock Titan ue, 10 Feb 2026 08
- Galecto CEO Transition and Major Shareholder-Approved Restructuring - The Globe and Mail Wed, 11 Feb 2026 08
- GLTO: UBS Initiates Coverage with a 'Buy' Rating and $45 PT | GL - GuruFocus ue, 17 Feb 2026 21
- Galecto Prices $275 Mln Public Offering At $19 Per Share, Stock Down - Nasdaq Wed, 11 Feb 2026 08
Insider Transactions
| Date | Shares | Url | Text | Insider | Position | Transaction | Start Date | Ownership | Value |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 8713000 | — | — | FAIRMOUNT FUNDS MANAGEMENT LLC | Director and Beneficial Owner of more than 10% of a Class of Security | — | 2026-02-09 00:00:00 | I | nan |
| 1 | 129000 | — | — | BRUNO JULIANNE | Director | — | 2026-02-09 00:00:00 | D | nan |
| 2 | 264629 | — | Stock Award(Grant) at price 0.00 per share. | HEWES LEMUEL BECKER | Officer | — | 2026-01-05 00:00:00 | D | — |
| 3 | 190376 | — | Stock Award(Grant) at price 0.00 per share. | SATTARZADEH SHERWIN | Chief Operating Officer | — | 2026-01-05 00:00:00 | D | — |
| 4 | 700 | — | Sale at price 21.38 per share. | SCHAMBYE HANS T. | Chief Executive Officer | — | 2026-01-02 00:00:00 | D | 14966.0 |
| 5 | 1360 | — | — | SCHAMBYE HANS T. | Chief Executive Officer | — | 2026-01-02 00:00:00 | D | nan |
| 6 | 255 | — | Sale at price 21.38 per share. | WINSLOW GARRETT | General Counsel | — | 2026-01-02 00:00:00 | D | 5452.0 |
| 7 | 680 | — | — | WINSLOW GARRETT | General Counsel | — | 2026-01-02 00:00:00 | D | nan |
| 8 | 135 | — | Sale at price 21.41 per share. | FIRMANI LORI | Chief Financial Officer | — | 2026-01-02 00:00:00 | D | 2890.0 |
| 9 | 374 | — | — | FIRMANI LORI | Chief Financial Officer | — | 2026-01-02 00:00:00 | D | nan |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -20.16M | -32.05M | -59.58M | -52.10M |
| TotalUnusualItems | -950.00K | -3.58M | -1.14M | 319.00K |
| TotalUnusualItemsExcludingGoodwill | -950.00K | -3.58M | -1.14M | 319.00K |
| NetIncomeFromContinuingOperationNetMinorityInterest | -21.44M | -38.35M | -61.62M | -51.75M |
| ReconciledDepreciation | 181.00K | 830.00K | 490.00K | 441.00K |
| EBITDA | -21.11M | -35.63M | -60.72M | -51.79M |
| EBIT | -21.29M | -36.46M | -61.21M | -52.23M |
| NetInterestIncome | 844.00K | 1.69M | 722.00K | 156.00K |
| InterestIncome | 844.00K | 1.69M | 722.00K | 156.00K |
| NormalizedIncome | -20.49M | -34.77M | -60.48M | -52.07M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -21.44M | -38.35M | -61.62M | -51.75M |
| TotalExpenses | 21.29M | 36.46M | 61.21M | 52.23M |
| TotalOperatingIncomeAsReported | -22.26M | -39.91M | -61.21M | -52.23M |
| DilutedAverageShares | 1.16M | 1.06M | 1.02M | 1.01M |
| BasicAverageShares | 1.16M | 1.06M | 1.02M | 1.01M |
| DilutedEPS | -18.53 | -36.08 | -60.75 | -51.25 |
| BasicEPS | -18.53 | -36.08 | -60.75 | -51.25 |
| DilutedNIAvailtoComStockholders | -21.44M | -38.35M | -61.62M | -51.75M |
| NetIncomeCommonStockholders | -21.44M | -38.35M | -61.62M | -51.75M |
| NetIncome | -21.44M | -38.35M | -61.62M | -51.75M |
| NetIncomeIncludingNoncontrollingInterests | -21.44M | -38.35M | -61.62M | -51.75M |
| NetIncomeContinuousOperations | -21.44M | -38.35M | -61.62M | -51.75M |
| TaxProvision | 41.00K | 0.00 | ||
| PretaxIncome | -21.40M | -38.35M | -61.62M | -51.75M |
| OtherIncomeExpense | -950.00K | -3.58M | -1.14M | 319.00K |
| SpecialIncomeCharges | -968.00K | -3.38M | 0.00 | |
| GainOnSaleOfPPE | 0.00 | 64.00K | 0.00 | |
| RestructuringAndMergernAcquisition | 968.00K | 3.45M | 0.00 | |
| GainOnSaleOfSecurity | 18.00K | -197.00K | -1.14M | 319.00K |
| NetNonOperatingInterestIncomeExpense | 844.00K | 1.69M | 722.00K | 156.00K |
| InterestIncomeNonOperating | 844.00K | 1.69M | 722.00K | 156.00K |
| OperatingIncome | -21.29M | -36.46M | -61.21M | -52.23M |
| OperatingExpense | 21.29M | 36.46M | 61.21M | 52.23M |
| ResearchAndDevelopment | 10.79M | 23.77M | 48.21M | 38.49M |
| SellingGeneralAndAdministration | 10.50M | 12.69M | 13.00M | 13.74M |
| GeneralAndAdministrativeExpense | 10.50M | 12.69M | 13.00M | 13.74M |
| OtherGandA | 10.50M | 12.69M | 13.00M | 13.74M |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 1.32M | 1.08M | 1.03M | 1.01M |
| ShareIssued | 1.32M | 1.08M | 1.03M | 1.01M |
| TotalDebt | 73.00K | 249.00K | 804.00K | 847.00K |
| TangibleBookValue | 14.47M | 32.33M | 61.75M | 117.22M |
| InvestedCapital | 14.47M | 32.33M | 61.75M | 117.22M |
| WorkingCapital | 15.64M | 30.94M | 52.80M | 105.56M |
| NetTangibleAssets | 15.83M | 32.33M | 61.75M | 117.22M |
| CapitalLeaseObligations | 73.00K | 249.00K | 804.00K | 847.00K |
| CommonStockEquity | 14.47M | 32.33M | 61.75M | 117.22M |
| PreferredStockEquity | 1.36M | |||
| TotalCapitalization | 15.83M | 32.33M | 61.75M | 117.22M |
| TotalEquityGrossMinorityInterest | 15.83M | 32.33M | 61.75M | 117.22M |
| StockholdersEquity | 15.83M | 32.33M | 61.75M | 117.22M |
| GainsLossesNotAffectingRetainedEarnings | 97.00K | 380.00K | -244.00K | -320.00K |
| OtherEquityAdjustments | 97.00K | 380.00K | -244.00K | -320.00K |
| RetainedEarnings | -277.52M | -256.08M | -217.74M | -156.11M |
| AdditionalPaidInCapital | 291.90M | 288.04M | 279.73M | 273.65M |
| CapitalStock | 1.36M | 0.00 | 0.00 | 0.00 |
| CommonStock | 0.00 | 0.00 | 0.00 | 0.00 |
| PreferredStock | 1.36M | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 1.30M | 5.90M | 11.44M | 4.99M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 104.00K | 66.00K | 328.00K | 448.00K |
| OtherNonCurrentLiabilities | 43.00K | |||
| LongTermDebtAndCapitalLeaseObligation | 61.00K | 66.00K | 328.00K | 448.00K |
| LongTermCapitalLeaseObligation | 61.00K | 66.00K | 328.00K | 448.00K |
| CurrentLiabilities | 1.20M | 5.83M | 11.11M | 4.54M |
| OtherCurrentLiabilities | 487.00K | 539.00K | 539.00K | 438.00K |
| CurrentDebtAndCapitalLeaseObligation | 12.00K | 183.00K | 476.00K | 399.00K |
| CurrentCapitalLeaseObligation | 12.00K | 183.00K | 476.00K | 399.00K |
| PensionandOtherPostRetirementBenefitPlansCurrent | 204.00K | 987.00K | 597.00K | 601.00K |
| PayablesAndAccruedExpenses | 494.00K | 4.12M | 9.49M | 3.11M |
| CurrentAccruedExpenses | 117.00K | 2.42M | 6.14M | 1.57M |
| Payables | 377.00K | 1.70M | 3.35M | 1.53M |
| AccountsPayable | 377.00K | 1.70M | 3.35M | 1.53M |
| TotalAssets | 17.13M | 38.23M | 73.19M | 122.22M |
| TotalNonCurrentAssets | 293.00K | 1.45M | 9.28M | 12.11M |
| OtherNonCurrentAssets | 163.00K | 1.13M | 2.28M | 2.03M |
| InvestmentsAndAdvances | 0.00 | 5.83M | 9.05M | |
| OtherInvestments | 5.83M | 9.05M | ||
| InvestmentinFinancialAssets | 0.00 | 5.83M | 9.05M | |
| AvailableForSaleSecurities | 5.83M | 9.05M | ||
| NetPPE | 130.00K | 325.00K | 1.17M | 1.04M |
| AccumulatedDepreciation | -50.00K | -29.00K | -62.00K | -20.00K |
| GrossPPE | 180.00K | 354.00K | 1.23M | 1.06M |
| OtherProperties | 180.00K | 354.00K | 1.23M | 1.06M |
| MachineryFurnitureEquipment | 223.00K | |||
| CurrentAssets | 16.84M | 36.77M | 63.91M | 110.10M |
| OtherCurrentAssets | 90.00K | 85.00K | 52.00K | 334.00K |
| CurrentDeferredAssets | 1.10M | 1.05M | 1.45M | 5.57M |
| PrepaidAssets | 590.00K | 774.00K | 805.00K | 1.73M |
| Receivables | 881.00K | 1.72M | 1.38M | 2.28M |
| TaxesReceivable | 881.00K | 1.72M | 1.38M | 2.28M |
| CashCashEquivalentsAndShortTermInvestments | 14.18M | 33.15M | 60.22M | 100.19M |
| OtherShortTermInvestments | 0.00 | 11.69M | 27.44M | 37.63M |
| CashAndCashEquivalents | 14.18M | 21.46M | 32.79M | 62.56M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -18.62M | -36.91M | -43.13M | -52.53M |
| IssuanceOfCapitalStock | 0.00 | 2.88M | 507.00K | 0.00 |
| CapitalExpenditure | -196.00K | -223.00K | ||
| IncomeTaxPaidSupplementalData | 0.00 | 0.00 | 0.00 | 0.00 |
| EndCashPosition | 14.18M | 21.46M | 32.79M | 62.56M |
| BeginningCashPosition | 21.46M | 32.79M | 62.56M | 163.84M |
| EffectOfExchangeRateChanges | -317.00K | 384.00K | 264.00K | -917.00K |
| ChangesInCash | -6.97M | -11.71M | -30.04M | -100.36M |
| FinancingCashFlow | 0.00 | 2.88M | 507.00K | 0.00 |
| CashFlowFromContinuingFinancingActivities | 0.00 | 2.88M | 507.00K | 0.00 |
| ProceedsFromStockOptionExercised | 0.00 | |||
| NetPreferredStockIssuance | 0.00 | |||
| PreferredStockIssuance | 0.00 | |||
| NetCommonStockIssuance | 0.00 | 2.88M | 507.00K | 0.00 |
| CommonStockIssuance | 0.00 | 2.88M | 507.00K | 0.00 |
| InvestingCashFlow | 11.65M | 22.33M | 12.38M | -48.05M |
| CashFlowFromContinuingInvestingActivities | 11.65M | 22.33M | 12.38M | -48.05M |
| NetInvestmentPurchaseAndSale | 11.65M | 22.25M | 12.58M | -47.83M |
| SaleOfInvestment | 11.65M | 48.18M | 57.45M | 36.38M |
| PurchaseOfInvestment | 0.00 | -25.94M | -44.87M | -84.21M |
| NetPPEPurchaseAndSale | 0.00 | 83.00K | -196.00K | -223.00K |
| SaleOfPPE | 0.00 | 83.00K | 0.00 | |
| PurchaseOfPPE | 0.00 | -196.00K | -223.00K | |
| OperatingCashFlow | -18.62M | -36.91M | -42.93M | -52.31M |
| CashFlowFromContinuingOperatingActivities | -18.62M | -36.91M | -42.93M | -52.31M |
| ChangeInWorkingCapital | -2.67M | -4.37M | 11.94M | -6.62M |
| ChangeInOtherCurrentLiabilities | -127.00K | -600.00K | -523.00K | -513.00K |
| ChangeInOtherCurrentAssets | 970.00K | 1.15M | -257.00K | -866.00K |
| ChangeInPayablesAndAccruedExpense | -4.46M | -4.98M | 6.49M | -1.05M |
| ChangeInAccruedExpense | -3.14M | -3.33M | 4.67M | 274.00K |
| ChangeInPayable | -1.32M | -1.65M | 1.82M | -1.32M |
| ChangeInAccountPayable | -1.32M | -1.65M | 1.82M | -1.32M |
| ChangeInPrepaidAssets | 954.00K | 65.00K | 6.23M | -4.20M |
| OtherNonCashItems | 1.99M | 46.00K | 58.00K | 75.00K |
| StockBasedCompensation | 3.24M | 5.43M | 5.57M | 4.48M |
| AmortizationOfSecurities | 70.00K | -431.00K | 566.00K | 1.07M |
| DepreciationAmortizationDepletion | 181.00K | 830.00K | 490.00K | 441.00K |
| DepreciationAndAmortization | 181.00K | 830.00K | 490.00K | 441.00K |
| Depreciation | 181.00K | 830.00K | 490.00K | 441.00K |
| OperatingGainsLosses | -64.00K | 70.00K | ||
| GainLossOnInvestmentSecurities | 70.00K | |||
| GainLossOnSaleOfPPE | 0.00 | -64.00K | 0.00 | |
| NetIncomeFromContinuingOperations | -21.44M | -38.35M | -61.62M | -51.75M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for GLTO
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|